Spruce Biosciences (NASDAQ:SPRB – Get Free Report) is expected to announce its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($5.79) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 4:00 PM ET.
Spruce Biosciences (NASDAQ:SPRB – Get Free Report) last posted its earnings results on Wednesday, May 13th. The company reported ($8.94) earnings per share for the quarter, missing the consensus estimate of ($7.93) by ($1.01). On average, analysts expect Spruce Biosciences to post $-22 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Spruce Biosciences Trading Down 1.4%
NASDAQ:SPRB opened at $46.20 on Tuesday. The stock’s 50 day moving average price is $48.50 and its 200 day moving average price is $57.78. The company has a market capitalization of $127.05 million, a PE ratio of -1.26 and a beta of 3.23. The company has a quick ratio of 4.67, a current ratio of 4.67 and a debt-to-equity ratio of 0.16. Spruce Biosciences has a 52-week low of $7.00 and a 52-week high of $240.00.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several equities research analysts have recently weighed in on the company. Craig Hallum initiated coverage on Spruce Biosciences in a report on Monday, April 27th. They issued a “buy” rating and a $140.00 price objective for the company. JonesTrading began coverage on shares of Spruce Biosciences in a report on Tuesday, June 9th. They issued a “buy” rating and a $135.00 target price on the stock. Guggenheim assumed coverage on shares of Spruce Biosciences in a research report on Tuesday, June 16th. They issued a “buy” rating and a $123.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spruce Biosciences in a research note on Friday, June 5th. Finally, B. Riley Financial assumed coverage on shares of Spruce Biosciences in a research report on Monday, July 13th. They set a “buy” rating and a $160.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $162.62.
Read Our Latest Research Report on SPRB
Spruce Biosciences Company Profile
Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.
The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.
Featured Stories
- Five stocks we like better than Spruce Biosciences
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
